Header

2nd Generation STING Agonist

A signaling molecule that plays a critical role in the cytosolic detection of tumor-derived DNA

BI 1703880: 2nd Generation STING agonist

BI 1703880* is a small molecule that binds to the stimulator of interferon (IFN) genes (STING).1 

Mechanism of action

STING functions as a DNA sensor and is expressed in immune cells, stromal cells and tumor cells. 

STING pathway activation by STING agonist induces the production of Type I IFN and inflammatory cytokine secretion in the tumor microenvironment (TME), leading to innate immune cell activation, cross-priming, activation, and infiltration of cytotoxic T cells and subsequent tumor cell killing.1-3

Preclinical data have shown that BI 1703880 potently and highly selectively activates the STING pathway, resulting in dose-dependent cytokine secretion. In vivo data (preclinical mouse tumor models) demonstrated induction of a tumor-specific immune response leading to complete anti-tumor response when administered in combination with anti-PD1.4 

Immuno-modulatory mechanism of action1,3

Immuno-modulatory MoA

CDN, cyclic dinucleotide; cGAS, cyclic GMP–AMP synthase; STING, stimulator of interferon genes.

Clinical development

BI 1703880 is currently being investigated in a Phase I trial as a combination with ezabenlimab (BI 754091)*, a programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced solid tumors.5

STING agonist (BI 1703880) clinical trial

Trial numberPhaseTreatmentPatient populationStatus

NCT05471856 (1480-0001)3

I

BI 1703880 + ezabenlimab (PD-1 inhibitor)

Advanced solid tumors

Recruiting

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
STING, stimulator of interferon genes.

You may also be interested in...

  1. Harrington K, et al. J Immunother Cancer. 2022;10(Suppl 2):A658. Abstract 626.

  2. Woo SR. Immunity. 2014;41(5):830–42.

  3. Barber GN. Nat Rev Immunol. 2015;15(12):760–70.

  4. Gremel G, et al. Cancer Res. 2020;80(16 Suppl.): Abstract 4522.

  5. ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856 (Accessed: April 2024). 

Share this page